Advertisement

Effect of Pelvic Lymph Node Irradiation in Salvage Therapy for Patients with Prostate Cancer with a Biochemical Relapse Following Radical Prostatectomy

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Radiation therapy (RT) as salvage treatment for a biochemical relapse following prostatectomy has been shown to be of benefit measured by serum prostate-specific antigen (PSA) control. However, identifying a target volume for RT has not been well established in this setting. In this study, the results of postoperative RT delivered to extended fields (EFs), prostatic fossa, and pelvic lymph nodes encompassing at least the obturator lymph nodes are compared with treatment of limited fields (LFs), prostatic fossa only, as salvage treatment for patients with a biochemical relapse. Between 1987 and 1999, 68 patients were referred for postprostatectomy RT. Of these patients, 46 were treated for salvage intent by RT alone without adjuvant hormones, 21 patients were treated to EFs and 25 treated to LFs. All patients were treated using 4-field plans. The mean field sizes measured 15 × 14 cm (AP/PA fields) and 12 × 14 cm LFs for the EFs and 10 × 10 cm (AP/PA fields) and 10 × 10 cm (lateral fields) for the LFs. The mean total doses for the EFs and LFs were 6300 and 6200 cGy, respectively, using 180-cGy daily increments. All patients treated to the EFs received boost doses to the prostatic fossa after 4500 cGy total dose to the pelvis. The 10-year actuarial biochemical diseasefree survival (DFS) rates for the EF and LF groups were 52% and 47%, respectively (P = 0.523). The distant metastasis-free survival (DMFS) rates were 77% and 78% (P = 0.925), and overall survival (OS) rates were 88% and 68% (P = 0.615) for the EF and LF group, respectively. A subset analysis of patients with adverse pathologic features (including tumor-involved surgical margins, lymph node involvement, seminal vesicle involvement, extracapsular extension, and/or perineural invasion) showed biochemical DFS rates of 57% and 44% (P = 0.217) for the EF and LF groups, respectively. The DMFS rates were 84% and 72% (P = 0.423), and OS rates 92% and 61% (P = 0.366) for the EF and LF groups, respectively. For patients with increasing PSA levels after a radical prostatectomy, salvage irradiation is a viable option for biochemical control. Our results suggest that EF radiation with coverage of pelvic lymph nodes shows a trend toward better PSA control in those with adverse pathologic features, although statistical significance was not achieved because of the limited number of patients who satisfied the restricted criteria excluding use of adjuvant hormones.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • American Cancer Society
        Cancer Facts & Figures 2004. ACS, Atlanta, GA2004
        • Lightner DJ
        • Lange PH
        • Reddy PK
        Prostate specific antigen and local recurrence rate following radical prostatectomy for prostate cancer.
        J Urol. 1990; 144: 921-926
        • Peschel RE
        Prostate specific antigen following radiation therapy.
        Int J Radiat Oncol Biol Phys. 1996; 36: 749-750
        • Zietman AL
        • Shipley WU
        • Coen JJ
        Radical prostatectomy and radiation therapy for clinical stages T1 and T2 adenocarcinoma of the prostate: new insights into outcome from repeated biopsy and prostate-specific antigen follow-up.
        J Urol. 1994; 152: 1806-1812
        • Oesterling JE
        Prostate-specific antigen: a valuable clinical tool.
        Oncology (Huntingt). 1991; 5: 107-121
        • Schild SE
        • Buskirk SJ
        • Wong WW
        • et al.
        The use of radiotherapy for patients with isolated elevation of serum PSA levels following radical prostatectomy.
        J Urol. 1996; 156: 1725-1729
        • Morris MM
        • Dallow KC
        • Zietman AL
        • et al.
        Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer.
        Int J Radiat Oncol Biol Phys. 1997; 38: 731-736
        • Wu JJ
        • King SC
        • Montana GS
        • et al.
        The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen.
        Int J Radiat Oncol Biol Phys. 1995; 32: 317-323
        • McCarthy JF
        • Catalona WJ
        • Hudson MA
        Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: Early versus delayed therapy.
        J Urol. 1994; 151: 1575-1578
        • Kaplan ID
        • Bagshaw MA
        Serum prostate-specific antigen after postprostatectomy radiotherapy.
        Urology. 1992; 39: 401-406
        • Link P
        • Freiha FS
        • Stamey TA
        Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy.
        J Urol. 1991; 45: 532-534
        • Lange PH
        • Lightner DJ
        • Medini E
        • et al.
        The effect of radiation therapy after radical prostatectomy in patients with elevated prostate-specific antigen levels.
        J Urol. 1990; 44: 927-932
        • Stamey TA
        • Kabalin JN
        • McNeal E
        • et al.
        Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: II. Radical prostatectomy treated patients.
        J Urol. 1989; 141: 1076
        • Do LV
        • Do TM
        • Smith R
        • Parker RG
        Postoperative radiotherapy for carcinoma of the prostate.
        Am J Clin Oncol. 2002; 25: 1-8
        • Roach M
        • DeSilvio M
        • Lawton C
        • et al.
        Phase III trial comparing wholepelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.
        J Clin Oncol. 2003; 21: 1904-1911
        • Schild SE
        Radiation therapy after prostatectomy: Now or later?.
        Semin Radiat Oncol. 1998; 8: 132-139
        • Coia LR
        • Minsky BD
        • John M
        • et al.
        1996 decision trees and management guidelines.
        Semin Radiat Oncol. 1997; 7: 163
        • Kaplan E
        • Meier P
        Nonparametric estimation from incomplete observations.
        J Am Stat Assoc. 1958; 53: 457-481
        • Connolly JA
        • Shinohara K
        • Presti JC
        • et al.
        Local recurrence after radical prostatectomy: Characteristics in size, locations, and relationship to PSA and surgical margins.
        Urol. 1996; 47: 225-231
        • Anscher MS
        • Prosnitz LR
        Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement, and/or penetration through the capsule.
        J Urol. 1996; 138: 1407-1412
        • Syndikus I
        • Pickles T
        • Kostashuk E
        • et al.
        Postoperative radiotherapy for pT3 carcinoma of the prostate: improved local control.
        J Urol. 1996; 155: 1983-1986
        • Zagars GK
        • von Eschenbach AC
        • Ayala AG
        • et al.
        The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy.
        Cancer. 1991; 68: 2370-2377
        • Coen JJ
        • Zietman AL
        • Thakral H
        • et al.
        Radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastasis.
        J Clin Oncol. 2002; 20: 3199-3205
        • Vicini Fam Ziaja EL
        • Kestin LL
        • et al.
        Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer.
        Urology. 1999; 54: 111-117
        • Kalapurakai JA
        • Huang CF
        • Neriamparampil MM
        • et al.
        Biochemical DFS following adjuvant and salvage irradiation after radical prostatectomy.
        Int J Radiat Oncol Biol Phys. 2002; 54: 1047-1054